Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. It is characterized by an irreversible loss of lung function, leading to high morbidity and mortality; most patients die within three to five years following diagnosis. Pirfenidone (Roche’s Esbriet) and nintedanib (Boehringer Ingelheim’s Ofev) are the only two drugs approved for treatment of adults with IPF. In addition to these two disease-modifying therapies (DMTs), physicians prescribe off-label medications (e.g., corticosteroids, anticoagulants) to treat IPF patients when the risk/benefit profile does not warrant treatment with pirfenidone or nintedanib, or when patients cannot access these DMTs. Our Treatment Algorithms study provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients, providing insight into the current treatment landscape for IPF.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.